Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract.
BACKGROUND
Food allergy may be life-threatening, and patients affected need to receive accurate diagnoses and treatment. Hazelnut has often been implicated as responsible for allergic reactions, and trace quantities can induce systemic reactions.


OBJECTIVE
The aim of this study was to evaluate the efficacy and tolerance of sublingual immunotherapy with a standardized hazelnut extract in patients allergic to hazelnut.


METHODS
This was a randomized, double-blind, placebo-controlled study. Inclusion criteria were a history of hazelnut allergy and positive skin prick test and double-blind placebo-controlled food challenge results. Patients were then randomly assigned into 2 treatment groups (hazelnut immunotherapy or placebo). Efficacy was assessed by double-blind, placebo-controlled food challenge after 8 to 12 weeks of treatment. Blood samples were drawn for measurement of specific IgE, IgG(4), and serum cytokines before and after treatment.


RESULTS
Twenty-three patients were enrolled and divided into 2 treatment groups. Twenty-two patients reached the planned maximum dose at 4 days. Systemic reactions were observed in only 0.2% of the total doses administered. Mean hazelnut quantity provoking objective symptoms increased from 2.29 g to 11.56 g (P = .02; active group) versus 3.49 g to 4.14 g (placebo; NS). Moreover, almost 50% of patients who underwent active treatment reached the highest dose (20 g), but only 9% in the placebo. Laboratory data showed an increase in IgG(4) and IL-10 levels after immunotherapy in only the active group.


CONCLUSIONS
Our data confirm significant increases in tolerance to hazelnut after sublingual immunotherapy as assessed by double-blind, placebo-controlled food challenge, and good tolerance to this treatment.
Enrique
Ernesto
E
Allergy Department, Hospital General de Castellón, Castellón, Spain. eenriquemiranda@hotmail.com
Pineda
Fernando
F
Malek
Tamim
T
Bartra
Joan
J
Basagaña
María
M
Tella
Raquel
R
Castelló
José Vicente
JV
Alonso
Rosario
R
de Mateo
José Antonio
JA
Cerdá-Trias
Teresa
T
San Miguel-Moncín
María del Mar
Mdel M
Monzón
Susana
S
García
María
M
Palacios
Ricardo
R
Cisteró-Bahíma
Anna
A
D000286:Administration, Sublingual; D000328:Adult; D031211:Corylus / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000097:blood; D007159:Immunologic Tests; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D008875:Middle Aged; D021184:Nut Hypersensitivity / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D010936:Plant Extracts / Q000008:administration & dosage; D016896:Treatment Outcome
D007074:Immunoglobulin G; D010936:Plant Extracts; D016753:Interleukin-10